Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Magnetar Financial LLC

Magnetar Financial LLC lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 52.9% in the first quarter, Holdings Channel reports. The institutional investor owned 6,313 shares of the life sciences company’s stock after selling 7,102 shares during the quarter. Magnetar Financial LLC’s holdings in Integra LifeSciences were worth $224,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares during the last quarter. Capital Research Global Investors lifted its stake in Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after buying an additional 1,621,655 shares during the last quarter. Cooke & Bieler LP lifted its stake in Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after buying an additional 120,410 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in Integra LifeSciences by 10.3% in the first quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock valued at $95,289,000 after buying an additional 252,015 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Integra LifeSciences by 4.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock valued at $70,340,000 after purchasing an additional 63,323 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Insider Activity

In other news, Chairman Stuart Essig purchased 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the acquisition, the chairman now directly owns 487,922 shares in the company, valued at $13,900,897.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.10% of the stock is owned by corporate insiders.

Integra LifeSciences Stock Down 23.4 %

NASDAQ IART traded down $7.35 during trading on Monday, reaching $24.08. 1,356,935 shares of the company’s stock were exchanged, compared to its average volume of 1,090,631. Integra LifeSciences Holdings Co. has a fifty-two week low of $22.36 and a fifty-two week high of $46.09. The firm has a market capitalization of $1.90 billion, a PE ratio of 62.86, a P/E/G ratio of 1.14 and a beta of 1.11. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15. The company’s fifty day simple moving average is $29.75 and its 200-day simple moving average is $33.78.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The business had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The firm’s revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.74 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Bank of America lowered their price target on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a report on Tuesday, May 7th. Truist Financial lifted their target price on Integra LifeSciences from $25.00 to $32.00 and gave the stock a “hold” rating in a report on Tuesday, July 16th. Morgan Stanley lifted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. JMP Securities lowered their target price on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th. Finally, Citigroup lifted their target price on Integra LifeSciences from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $32.86.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.